Study on carbon emission reduction countermeasures based on carbon emission influencing factors and trends.

The carbon mitigation response encompasses a variety of strategies aimed at mitigating greenhouse gas emissions resulting from human activities. These measures are crafted to address the challenges posed by climate change and facilitate the transition of businesses towards a low-carbon paradigm. Leveraging the analytical outcomes of the extended STIRPAT model and the PSO-BP prediction model, this paper suggests countermeasures for reducing carbon emissions in China's metal smelting industry. The overarching objective is to contribute to China's attainment of the "dual carbon objectives." The study identifies key factors influencing carbon emissions in the metal smelting industry, ranked in descending order of sensitivity: population, coal consumption, urbanization rate, total metal production, carbon intensity, proportion of secondary industry, and GDP per capita. Results from three established scenarios-namely, low carbon, standard, and high carbon-indicate a consistent decline in carbon emissions from China's metal smelting industry over the next 15 years. This research not only enhances the findings of existing studies on carbon emissions in the metal smelting sector but also introduces an innovative approach to carbon emission reduction within China's metal smelting industry.

A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis.

BACKGROUND: Fibroblast growth factor 21 (FGF21) has become a promising therapeutic target for metabolic diseases such as type 2 diabetes (T2D), obesity and non-alcoholic steatohepatitis. However, the clinical application of natural FGF21 molecule is limited because of its instability in vitro and short half-life in vivo. To improve FGF21's therapeutic property, we screened high receptor binding FGF21 analogs and made FGF21-Fc-GLP-1 dual-targeted constructs to investigate their activity in a number of experiments . METHODS: Utilizing phage display high-throughput screening we identified mutations that could improve ß-Klotho binding property of FGF21. IgG4 Fc was fused to FGF21 variants to extend the in vivo half-life. We further explored the potential synergistic actions of FGF21 with the incretin glucagon-like peptide-1 (GLP-1) by generating GLP-1-Fc-FGF21 dual agonists. FINDINGS: Two Fc-FGF21 variants showed enhanced ß-Klotho binding affinity in vitro as well as improved glucose lowering effect in vivo. One of the dual agonists, GLP-1-Fc-FGF21 D1, provided potent and sustained glucose lowering effect in diabetic mice models. It also demonstrated superior weight loss effect to GLP-1 or FGF21 alone. Moreover, GLP-1-Fc-FGF21 D1 exhibited strong anti-NASH effect in the high-fat diet-induced ob/ob model as it improved liver function, serum and hepatic lipid profile and reduced NAFLD activity score with an efficacy superior to either FGF21 or GLP-1 analogs alone. INTERPRETATION: This novel GLP-1/FGF21 dual agonist is worth clinical development for the treatment of T2D, obesity and NASH. FUNDING: HEC Pharm R&D Co., Ltd, National natural science fund of China.